Gilead Sciences (GILD) vs Eli Lilly (LLY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eli Lilly (LLY) has outperformed Gilead Sciences (GILD) over the past year, gaining 40.9% versus a gain of 25.7%. Over five years, LLY leads with a +399.7% price change compared with +117.1% for GILD. Eli Lilly is the larger company by market cap ($1.06 trillion vs $182.09 billion), about 5.8 times the size.
On valuation, Gilead Sciences trades at a lower forward P/E (14.8x vs 25.0x for Eli Lilly). Gilead Sciences offers the higher dividend yield (2.19% vs 0.54%). Eli Lilly converts more of its revenue into profit, with a net margin of 31.7% versus 28.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GILD | LLY |
|---|---|---|
| Share price | $146.85 | $1,188.72 |
| Market cap | $182.09B | $1.06T |
| 1-day change | +1.82% | +2.70% |
| YTD return | +19.64% | +10.61% |
| 1-year return | +25.75% | +40.91% |
| 5-year return | +117.14% | +399.71% |
| P/E ratio (TTM) | — | 38.86 |
| Forward P/E | 14.85 | 24.98 |
| EPS (TTM) | $-2.70 | $30.59 |
| Dividend yield | 2.19% | 0.54% |
| Annual dividend | $3.22 | $6.46 |
| Revenue (latest FY) | $29.44B | $65.18B |
| Revenue growth (YoY) | +2.40% | +44.70% |
| Net income (latest FY) | $8.51B | $20.64B |
| Gross margin | 78.83% | 83.04% |
| Operating margin | 34.04% | — |
| Net margin | 28.90% | 31.67% |
| 52-week high | $157.29 | $1,292.65 |
| 52-week low | $114.02 | $783.85 |
| Distance from 52-week high | -6.64% | -8.04% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +8.46% | +11.82% |
| Average volume | 6.02M | 2.48M |
| Shares outstanding | 1.24B | 891.74M |
| Employees | 17,000 | 50,000 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - General | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eli Lilly is about 5.8 times larger than Gilead Sciences by market value ($1.06T vs $182.09B).
- LLY has outperformed GILD by 15.2 percentage points over the past year.
- Gilead Sciences offers a meaningfully higher dividend yield (2.19% vs 0.54%).
- Eli Lilly grew revenue faster in its latest fiscal year (+44.70% vs +2.40%).
- The two companies sit in different sectors: Gilead Sciences in Healthcare and Eli Lilly in Health Care.
About Gilead Sciences
GILD stock →Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Healthcare · Drug Manufacturers - General · 17,000 employees
About Eli Lilly
LLY stock →Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 50,000 employees
GILD vs LLY FAQ
Which is bigger, Gilead Sciences or Eli Lilly?
Eli Lilly (LLY) is larger, with a market capitalization of $1.06T compared with $182.09B for Gilead Sciences (GILD).
Which stock has performed better over the past year, GILD or LLY?
LLY returned +40.91% over the past 12 months, compared with +25.75% for GILD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Gilead Sciences or Eli Lilly?
Gilead Sciences has the higher yield at 2.19%, compared with 0.54% for Eli Lilly.
Are Gilead Sciences and Eli Lilly in the same industry?
No. Gilead Sciences is in the Healthcare sector, while Eli Lilly is in Health Care.